Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that it and longtime partner, Merck, known as MSD outside of the United States and Canada, have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.